在异性造血细胞移植后的EASIX和心脏不良事件
Carles Tolosa-Ridao1,2, Enric Cascos3, Luis Gerardo Rodríguez-Lobato2,4
1Hematology Department, Hospital Universitari Mútua Terrassa, Barcelona, Spain.
Bone marrow transplantation
|March 24, 2024
概括
通过EASIX测量的内皮激活,预测了全源造血干细胞移植 (allo-HCT) 后的心脏不良事件 (CAE). 较高的EASIX分数表明在移植后的第一年内CAE的风险增加.
科学领域:
- 血液学 血液学 血液学
- 心脏病学 心脏病学
- 移植免疫学 移植免疫学
背景情况:
- 全基性造血干细胞移植 (allo-HCT) 与包括心脏不良事件 (CAE) 在内的重大风险有关.
- 内皮细胞激活与CAE的病理生理学有关,其次是alo-HCT.
- 早期识别CAE风险患者对于及时干预至关重要.
研究的目的:
- 调查由内皮细胞激活和压力指数 (EASIX) 评估的内皮细胞激活与外围血液alo-HCT后第一年内CAE发生率之间的关联.
- 确定EASIX是否可以在接受alo-HCT.患者中作为CAE的预测标志物.
主要方法:
- 在2012年至2021年期间,对437名接受了外周血液alo-HCT的成年患者进行了回顾性分析.
- EASIX分数在合并HCT后的前六个月和前六个月内计算,并用于统计分析进行log2转换.
- 进行了回归分析,以确定CAE的预测因素.
主要成果:
- 一年的CAE发病率为12.6%,心力衰竭和心律失常是最常见的事件.
- 患有CAE的患者在allo-HCT后的前6个月内显著增加了EASIX趋势.
- 较高的log2-EASIX值被证实是第一年内CAE风险增加的显著预测因素.
结论:
- 较高的EASIX分数表明,内皮激活升高与alo-HCT后心脏毒性风险增加有显著的关联.
- EASIX是一个有价值的工具,用于识别在合并HCT后的第一年CAE风险较高的患者.
- 这些发现支持扩大EASIX的使用范围,以对所有HCT接受者进行风险分层.
更多相关视频
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.3K
09:25An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
Published on: May 8, 2020
7.9K
相关概念视频
01:22Bone Marrow Sampling and Transplants
328
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
328
01:19Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K